Loading…
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma
Highlights • Novel treatment strategy for overcoming poor prognosis of EBV-positive DLBCL is needed. • The histone deacetylase inhibitor romidepsin shows selective cytotoxicity in EBV-positive DLBCL. • Romidepsin inhibits the expression of LMP1 and c-myc in EBV-positive cells. • Dual inhibition of L...
Saved in:
| Published in: | Cancer letters 2015-08, Vol.364 (2), p.89-97 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c511t-47b548691e60d5708614d1310c7f6f336cffa03f331ac970fff976a6eca022553 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c511t-47b548691e60d5708614d1310c7f6f336cffa03f331ac970fff976a6eca022553 |
| container_end_page | 97 |
| container_issue | 2 |
| container_start_page | 89 |
| container_title | Cancer letters |
| container_volume | 364 |
| creator | Shin, Dong-Yeop Kim, Areumnuri Kang, Hye Jin Park, Sunhoo Kim, Dong Wan Lee, Seung-Sook |
| description | Highlights • Novel treatment strategy for overcoming poor prognosis of EBV-positive DLBCL is needed. • The histone deacetylase inhibitor romidepsin shows selective cytotoxicity in EBV-positive DLBCL. • Romidepsin inhibits the expression of LMP1 and c-myc in EBV-positive cells. • Dual inhibition of LMP1 and c-myc activates EBV lytic cycle in EBV-positive cells. • Romidepsin could be a promising agent for treating EBV-positive DLBCL. |
| doi_str_mv | 10.1016/j.canlet.2015.03.016 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1727684587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0304383515001962</els_id><sourcerecordid>3699680921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-47b548691e60d5708614d1310c7f6f336cffa03f331ac970fff976a6eca022553</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEoqXwBghZ4sIlyziO7eSCRKtCkRaBxJ-r5XXGrRcnTu1kYd-LB8TRLiD10pOt8W--mfF8RfGcwooCFa-3K6MHj9OqAspXwFY5-KA4pY2sStk28LA4BQZ1yRrGT4onKW0BgNeSPy5OKi5baEGeFr-vXJrCgKRDbXDae52QuOHGbdwUIomhdx2OyQ052M0GE0FrnXE4TGSa-4wY9J74fXKJ7JwmCT2aye2yYvg5lBGvZ68nFwYSLFl__EyJHjpiyn5vCP4aI6a0POYCl-ffyzEkd0h21s65Fa_jNZLz8lilH29Cr58Wj6z2CZ8dz7Pi27vLrxdX5frT-w8Xb9el4ZROZS03vG5ES1FAxyU0gtYdZRSMtMIyJoy1Gli-UW1aCdbaVgot0GioKs7ZWfHqoDvGcDtjmlTv0tKJHjDMSVFZSdHUvJH3o6IRNbRVzTL68g66DXMc8iALVVfQtC1kqj5QJoaUIlo1RtfruFcU1GIAtVUHA6jFAAqYysGc9uIoPm967P4l_d14Bt4cAMwft3MYVVq2abBzMS9OdcHdV-GugPFucEb7H7jH9H8WlSoF6stiwsWDlAPQVlTsD4v32hA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1684208990</pqid></control><display><type>article</type><title>Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma</title><source>ScienceDirect Freedom Collection</source><creator>Shin, Dong-Yeop ; Kim, Areumnuri ; Kang, Hye Jin ; Park, Sunhoo ; Kim, Dong Wan ; Lee, Seung-Sook</creator><creatorcontrib>Shin, Dong-Yeop ; Kim, Areumnuri ; Kang, Hye Jin ; Park, Sunhoo ; Kim, Dong Wan ; Lee, Seung-Sook</creatorcontrib><description>Highlights • Novel treatment strategy for overcoming poor prognosis of EBV-positive DLBCL is needed. • The histone deacetylase inhibitor romidepsin shows selective cytotoxicity in EBV-positive DLBCL. • Romidepsin inhibits the expression of LMP1 and c-myc in EBV-positive cells. • Dual inhibition of LMP1 and c-myc activates EBV lytic cycle in EBV-positive cells. • Romidepsin could be a promising agent for treating EBV-positive DLBCL.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2015.03.016</identifier><identifier>PMID: 25790907</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Animals ; Antibiotics, Antineoplastic - pharmacology ; Apoptosis ; c-myc ; Cancer ; Cancer therapies ; Cell Line, Tumor ; Clinical trials ; Cytotoxicity ; Depsipeptides - pharmacology ; Diffuse large B-cell lymphoma ; Down-Regulation - drug effects ; Epstein-Barr virus ; Epstein-Barr Virus Infections - pathology ; Epstein-Barr Virus Infections - virology ; Female ; Hematology, Oncology and Palliative Medicine ; Herpesvirus 4, Human - drug effects ; Herpesvirus 4, Human - genetics ; Herpesvirus 4, Human - metabolism ; Histone Deacetylase Inhibitors - pharmacology ; Humans ; Latent membrane protein-1 ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - virology ; Medical research ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Polymerase chain reaction ; Proteins ; Proto-Oncogene Proteins c-myc - biosynthesis ; Proto-Oncogene Proteins c-myc - genetics ; Random Allocation ; Romidepsin ; Studies ; Viral Matrix Proteins - biosynthesis ; Viral Matrix Proteins - genetics ; Xenograft Model Antitumor Assays</subject><ispartof>Cancer letters, 2015-08, Vol.364 (2), p.89-97</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Aug 10, 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-47b548691e60d5708614d1310c7f6f336cffa03f331ac970fff976a6eca022553</citedby><cites>FETCH-LOGICAL-c511t-47b548691e60d5708614d1310c7f6f336cffa03f331ac970fff976a6eca022553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25790907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shin, Dong-Yeop</creatorcontrib><creatorcontrib>Kim, Areumnuri</creatorcontrib><creatorcontrib>Kang, Hye Jin</creatorcontrib><creatorcontrib>Park, Sunhoo</creatorcontrib><creatorcontrib>Kim, Dong Wan</creatorcontrib><creatorcontrib>Lee, Seung-Sook</creatorcontrib><title>Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights • Novel treatment strategy for overcoming poor prognosis of EBV-positive DLBCL is needed. • The histone deacetylase inhibitor romidepsin shows selective cytotoxicity in EBV-positive DLBCL. • Romidepsin inhibits the expression of LMP1 and c-myc in EBV-positive cells. • Dual inhibition of LMP1 and c-myc activates EBV lytic cycle in EBV-positive cells. • Romidepsin could be a promising agent for treating EBV-positive DLBCL.</description><subject>Animals</subject><subject>Antibiotics, Antineoplastic - pharmacology</subject><subject>Apoptosis</subject><subject>c-myc</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Clinical trials</subject><subject>Cytotoxicity</subject><subject>Depsipeptides - pharmacology</subject><subject>Diffuse large B-cell lymphoma</subject><subject>Down-Regulation - drug effects</subject><subject>Epstein-Barr virus</subject><subject>Epstein-Barr Virus Infections - pathology</subject><subject>Epstein-Barr Virus Infections - virology</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Herpesvirus 4, Human - drug effects</subject><subject>Herpesvirus 4, Human - genetics</subject><subject>Herpesvirus 4, Human - metabolism</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Latent membrane protein-1</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - virology</subject><subject>Medical research</subject><subject>Mice</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>Polymerase chain reaction</subject><subject>Proteins</subject><subject>Proto-Oncogene Proteins c-myc - biosynthesis</subject><subject>Proto-Oncogene Proteins c-myc - genetics</subject><subject>Random Allocation</subject><subject>Romidepsin</subject><subject>Studies</subject><subject>Viral Matrix Proteins - biosynthesis</subject><subject>Viral Matrix Proteins - genetics</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqFks9u1DAQxiMEoqXwBghZ4sIlyziO7eSCRKtCkRaBxJ-r5XXGrRcnTu1kYd-LB8TRLiD10pOt8W--mfF8RfGcwooCFa-3K6MHj9OqAspXwFY5-KA4pY2sStk28LA4BQZ1yRrGT4onKW0BgNeSPy5OKi5baEGeFr-vXJrCgKRDbXDae52QuOHGbdwUIomhdx2OyQ052M0GE0FrnXE4TGSa-4wY9J74fXKJ7JwmCT2aye2yYvg5lBGvZ68nFwYSLFl__EyJHjpiyn5vCP4aI6a0POYCl-ffyzEkd0h21s65Fa_jNZLz8lilH29Cr58Wj6z2CZ8dz7Pi27vLrxdX5frT-w8Xb9el4ZROZS03vG5ES1FAxyU0gtYdZRSMtMIyJoy1Gli-UW1aCdbaVgot0GioKs7ZWfHqoDvGcDtjmlTv0tKJHjDMSVFZSdHUvJH3o6IRNbRVzTL68g66DXMc8iALVVfQtC1kqj5QJoaUIlo1RtfruFcU1GIAtVUHA6jFAAqYysGc9uIoPm967P4l_d14Bt4cAMwft3MYVVq2abBzMS9OdcHdV-GugPFucEb7H7jH9H8WlSoF6stiwsWDlAPQVlTsD4v32hA</recordid><startdate>20150810</startdate><enddate>20150810</enddate><creator>Shin, Dong-Yeop</creator><creator>Kim, Areumnuri</creator><creator>Kang, Hye Jin</creator><creator>Park, Sunhoo</creator><creator>Kim, Dong Wan</creator><creator>Lee, Seung-Sook</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20150810</creationdate><title>Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma</title><author>Shin, Dong-Yeop ; Kim, Areumnuri ; Kang, Hye Jin ; Park, Sunhoo ; Kim, Dong Wan ; Lee, Seung-Sook</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-47b548691e60d5708614d1310c7f6f336cffa03f331ac970fff976a6eca022553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Antibiotics, Antineoplastic - pharmacology</topic><topic>Apoptosis</topic><topic>c-myc</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Clinical trials</topic><topic>Cytotoxicity</topic><topic>Depsipeptides - pharmacology</topic><topic>Diffuse large B-cell lymphoma</topic><topic>Down-Regulation - drug effects</topic><topic>Epstein-Barr virus</topic><topic>Epstein-Barr Virus Infections - pathology</topic><topic>Epstein-Barr Virus Infections - virology</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Herpesvirus 4, Human - drug effects</topic><topic>Herpesvirus 4, Human - genetics</topic><topic>Herpesvirus 4, Human - metabolism</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Latent membrane protein-1</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - virology</topic><topic>Medical research</topic><topic>Mice</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>Polymerase chain reaction</topic><topic>Proteins</topic><topic>Proto-Oncogene Proteins c-myc - biosynthesis</topic><topic>Proto-Oncogene Proteins c-myc - genetics</topic><topic>Random Allocation</topic><topic>Romidepsin</topic><topic>Studies</topic><topic>Viral Matrix Proteins - biosynthesis</topic><topic>Viral Matrix Proteins - genetics</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shin, Dong-Yeop</creatorcontrib><creatorcontrib>Kim, Areumnuri</creatorcontrib><creatorcontrib>Kang, Hye Jin</creatorcontrib><creatorcontrib>Park, Sunhoo</creatorcontrib><creatorcontrib>Kim, Dong Wan</creatorcontrib><creatorcontrib>Lee, Seung-Sook</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shin, Dong-Yeop</au><au>Kim, Areumnuri</au><au>Kang, Hye Jin</au><au>Park, Sunhoo</au><au>Kim, Dong Wan</au><au>Lee, Seung-Sook</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2015-08-10</date><risdate>2015</risdate><volume>364</volume><issue>2</issue><spage>89</spage><epage>97</epage><pages>89-97</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Highlights • Novel treatment strategy for overcoming poor prognosis of EBV-positive DLBCL is needed. • The histone deacetylase inhibitor romidepsin shows selective cytotoxicity in EBV-positive DLBCL. • Romidepsin inhibits the expression of LMP1 and c-myc in EBV-positive cells. • Dual inhibition of LMP1 and c-myc activates EBV lytic cycle in EBV-positive cells. • Romidepsin could be a promising agent for treating EBV-positive DLBCL.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>25790907</pmid><doi>10.1016/j.canlet.2015.03.016</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2015-08, Vol.364 (2), p.89-97 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1727684587 |
| source | ScienceDirect Freedom Collection |
| subjects | Animals Antibiotics, Antineoplastic - pharmacology Apoptosis c-myc Cancer Cancer therapies Cell Line, Tumor Clinical trials Cytotoxicity Depsipeptides - pharmacology Diffuse large B-cell lymphoma Down-Regulation - drug effects Epstein-Barr virus Epstein-Barr Virus Infections - pathology Epstein-Barr Virus Infections - virology Female Hematology, Oncology and Palliative Medicine Herpesvirus 4, Human - drug effects Herpesvirus 4, Human - genetics Herpesvirus 4, Human - metabolism Histone Deacetylase Inhibitors - pharmacology Humans Latent membrane protein-1 Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - virology Medical research Mice Mice, Inbred NOD Mice, SCID Polymerase chain reaction Proteins Proto-Oncogene Proteins c-myc - biosynthesis Proto-Oncogene Proteins c-myc - genetics Random Allocation Romidepsin Studies Viral Matrix Proteins - biosynthesis Viral Matrix Proteins - genetics Xenograft Model Antitumor Assays |
| title | Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T15%3A25%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20deacetylase%20inhibitor%20romidepsin%20induces%20efficient%20tumor%20cell%20lysis%20via%20selective%20down-regulation%20of%20LMP1%20and%20c-myc%20expression%20in%20EBV-positive%20diffuse%20large%20B-cell%20lymphoma&rft.jtitle=Cancer%20letters&rft.au=Shin,%20Dong-Yeop&rft.date=2015-08-10&rft.volume=364&rft.issue=2&rft.spage=89&rft.epage=97&rft.pages=89-97&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2015.03.016&rft_dat=%3Cproquest_cross%3E3699680921%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c511t-47b548691e60d5708614d1310c7f6f336cffa03f331ac970fff976a6eca022553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1684208990&rft_id=info:pmid/25790907&rfr_iscdi=true |